U.S. Markets open in 5 hrs 43 mins

Oncolytics Biotech Inc. (ONC.TO)

Toronto - Toronto Delayed Price. Currency in CAD
Add to watchlist
0.485-0.015 (-3.000%)
At close: 3:59PM EDT

Oncolytics Biotech Inc.

1167 Kensington Crescent, NW
Suite 210
Calgary, AB T2N 1X7

Full Time Employees

Key Executives

Dr. Matthew C. Coffey Ph.D., M.B.A.Chief Exec. Officer, Pres and Director568.07kN/AN/A
Mr. Kirk J. Look CAChief Financial Officer459.96kN/AN/A
Dr. Andres A. Gutierrez M.D., Ph.D.Chief Medical Officer75.04kN/A56
Mr. Andrew R. de GuttadauroPres of Oncolytics Biotech (U.S.) IncN/AN/A50
Dr. Daniel Douglas Von Hoff M.D., F.A.C.P.ConsultantN/AN/A69
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.


Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancers. The company is developing REOLYSIN, a systemically administered immune-oncology viral agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.

Corporate Governance

Oncolytics Biotech Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.